EFFECT OF NEURODEGENERATIVE CHANGES IN THE BRAIN ON THE FORMATION OF THE DISEASE CLINICAL PICTURE IN PATIENTS WITH MULTIPLE SCLEROSIS

The aim of the study was to determine the relationship of global and regional cerebral atrophy and volume of demyelination lesions in the brain with a clinical picture in patients with multiple sclerosis (MS). The study involved 55 patients with MS. Control group included 22 healthy volunteers. Patients were divided into groups according to the severity of disability, the type and duration of disease. Assessment of general and regional atrophy was performed by post-process volumetric segmentation of MRI data, which was acquired at 3T Philips Achieva scanner. The post-processing was done with the FreeSurfer software. It is shown that in MS patients brain atrophy develops both by means of gray matter (including the cortex and subcortical structures), and white matter, along with demyelination. Global and regional atrophy is associated with the severity of disability of patients according to EDSS scale, but not with the duration and type of the disease. Neurodegenerative changes of brain structures evolve with different rates, have different intensity and determine the set of symptoms of neurological impairment and severity of disability, which indicates the presence of certain patterns of the process of atrophy in the brain, forming the clinical picture of the disease.

multiple sclerosis, disability, neurodegeneration, MRI morphometry

1. Totoljan N.A. Diagnosis and differential diagnosis of idiopathic inflammatory demyelinating diseases of the central nervous system. Abstract for the degree of Doctor of Medical Sciences. St. Petersburg, 2004 (in Russian).

2. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci., 1986, vol. 9, pp. 357–381.

3. Bartzokis G., Beckson M., Lu P.H., Nuechterlein K.H., Ed wards N., et al. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch. Gen. Psychiatry, 2001, vol. 58, pp. 461–465.

4. Bermel R.A., Innus M.D., Tjoa C.W., Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport, 2003, vol. 14, pp. 335–339.

5. Bielekova B., Kadom N., Fisher E., Jeffries N., Ohayon J., Richert N., Howard T., Bash C.N., Frank J.A., Stone L., Martin R., Cutter G., McFarland H.F. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology, 2005, vol. 65, pp. 1071–1076.

6. Chard D.T., Griffin C.M., Rashid W., Davies G.R., Altmann D.R., Kapoor R., Barker G.J., Thompson A.J., Miller D.H. Progressive grey matter atrophy in clinically early relapsingremitting multiple sclerosis. Multiple Sclerosis, 2004, vol. 10, pp. 387–391.

7. Filippi M., Rocca M.A., Colombo B. et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage, 2002, vol. 15, pp. 559–567.

8. Fisniku L.K., Chard D.T., Jackson J.S., et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol., 2008, vol. 64, pp. 247–254.

9. Gasperini C., Paolillo A., Giugni E. et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult. Scler., 2002, vol. 8, pp. 119–123.

10. Henry R.G., Shieh M., Okuda D.T., Evangelista A., Gorno-Tempini M.L., Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at Presentation. J. Neurol. Neurosurg. Psychiatry, 2008, vol. 79, pp. 1236–1244.

11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983, vol. 33, no. 12, pp. 1444–1452.

12. Miller D.H., Barkhof F., Frank J.A., Parker G.J., Thompson A.J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain, 2002, vol. 125, pp. 1676–1695.

13. Postuma R.B., Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 Positron Emission Tomography and Functional Magnetic Resonance Imaging publications. Cerebral Cortex October, 2006, vol. 16, pp. 1508–1521.

14. Prinster A., Quarantelli M., Orefice G., Lanzillo R., Brunetti A., Mollica C., Salvatore E., Morra V.B., Copp ola G., Vacca G., Alfano B., Salvatore M. Grey matter loss in relapsing-remitting multiple sclerosis: A voxel-based morphometry study. Neuroimage, 2006, vol. 29, pp. 859–867.

15. Ramasamy D.P., Benedict R.H., Cox J.L., Fritz D., Abdelrahman N., Hussein S., Minagar A., Dwyer M.G., Zivadinov R. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J. Neurol. Sci., 2009, vol. 282, pp. 47–54

16. Rocca M.A., Mesaros S., Pagani E., Sormani M.P., Comi G., Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology, 2010, vol. 257, pp. 463–469.

17. Rudick R.A., Fisher E., Lee J.C., Duda J.T., Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult. Scler., 2000, vol. 6, pp. 365–372.

18. Shiee N., Bazin P-L., Zackowski K.M., Farrell S.K., Harrison D.M., et al. Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS ONE, 2012, vol. 7(5): e37049. doi:10.1371/journal.pone.0037049.

19. Valsasina P., Benedetti B., Rovaris M., Sormani M.P., Comi G., Filippi M. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology, 2005, vol. 65, pp. 1126–1128.

20. Walhovd K.B., Fjell A.M., Reinvang I., Lundervold A., Dale A., Eilertsen D.E., Quinn B., Salat D., Makris N., Fischl B. Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiology of Aging, 2005, vol. 26. (9) s., pp. 1261–1270.

21. Wiendl H., Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology, 2009, vol. 72, pp. 1008–1015.